City

Oklahoma City (1)

Seoul (1)

Condition

Mucinous Ovarian Cancer (2)

Cervical Cancer (1)

Endometrioid Cancer (1)

Fallopian Tube Cancer (1)

High Grade Serous Ovarian Cancer (1)

Primary Peritoneal Cancer (1)

Overall Status

Not yet recruiting (1)

Recruiting (1)

Sign in for free

Phase

phase 2 (2)

Sponsor

University of Oklahoma (1)

Yonsei University (1)

Collaborator

Verastem, Inc. (1)

Intervention

bevacizumab + modified folfirinox (1)

vs-6766 + defactinib (1)

Study Documents

Intervention Type

drug (2)

Funder Type

Other (2)

Study Type

Interventional (2)

mucinous ovarian cancer

Showing 1 - 2 of 2

Trials per page:

STUDY

CONDITIONS

INTERVENTIONS

LOCATIONS

Mucinous Ovarian Cancer, Fallopian Tube Cancer, Primary Peritoneal Cancer Trial in Seoul (Bevacizumab + modified FOLFIRINOX)

Recruiting

Mucinous Ovarian Cancer
+2 more

Bevacizumab + modified FOLFIRINOX

Seoul, Korea, Republic of

Yonsei University Health System, Severance Hospital

Dec 25, 2022

Endometrioid Cancer, Mucinous Ovarian Cancer, High Grade Serous Ovarian Cancer Trial in Oklahoma City (VS-6766 + defactinib)

Not yet recruiting

Endometrioid Cancer
+3 more

VS-6766 + defactinib

Oklahoma City, Oklahoma

Stephenson Cancer Center

Aug 19, 2022